Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281657 · ClinicalTrials.gov registry record
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 64
- Enrollment target
NCT01281657: Completed study, sponsored by Novartis.
NCT01281657 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01281657 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
The purpose of this observational study is to collect long-term data on safety and effectiveness of fingolimod, particularly including clinical disease and patient outcome related parameters such as relapse and disability, in patients who have participated in prior trials within the fingolimod clinical development program. Furthermore, this study explores the incidence of selected safety related outcomes of fingolimod treatment during follow-up visits within the context of routine medical practice.
Interventions
- DRUG fingolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-07 |
What the finished NCT01281657 record still lists
NCT01281657 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which fingolimod is the first listed.
NCT01281657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01281657 about?
NCT01281657 is a clinical study titled "Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program". The purpose of this observational study is to collect long-term data on safety and effectiveness of fingolimod, particularly including clinical disease and patient outcome related parameters such as relapse and disability, in patients who have participated in prior trials within the fingolimod clini...
What is the current status of trial NCT01281657?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2011-02. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01281657?
The interventions under investigation include: fingolimod (DRUG).
Who is sponsoring clinical trial NCT01281657?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia